



Incorporated in 1993, SIL (subsidiary of Biocon Ltd.) is one of the leading India – based contract research organization ("CRO"), offering a suite of integrated, end to end discovery and development services for novel molecular entities across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition companies. SIL service offerings in discovery and development cover multiple domains across small molecules, large molecules, antibody – drug conjugates and oligonucleotides. Its integrated discovery and development platforms help organizations conduct discovery (from hit to candidate selection), development (including pre –clinical and clinical studies, analytical and bio-analytical evaluation, formulation development and stability studies) and pilot manufacturing (scale – up, pre-clinical and clinical supplies) under one roof with a distinctive economic advantage. In addition, also supports the development of bio-similar and generic molecules. The Company offers services through flexible business models that are customized to its client requirements. These range from a full – time equivalent ("FTE") to fee – for – sevice ("FFS") model or a combination thereof. In FY15, the revenues from the sale of services stood at Rs. 8,427 mn. SIL derived 36.1% and 63.9% of its revenue from the sale of services from long term contracts with dedicated infrastructure and other contracts.

Worldclass Infrastructure - The company delivers services through a combination of scientific talent, globally accredited systems and research and development (R&D) infrastructure. As of March 31, 2015, gross block stood at Rs.9,311 mn. It has laboratory and manufacturing facilities which are spread in morethan 900,000 sq ft, located in Bengaluru, India. As of March 31, 2015, the company has 2,122 scientists, including 258 PhDs and 1,665 scientists with master's degree.

Attractive and diversified client base with several client collaborations - In FY15, SIL serviced 221 clients, ranging from multinational corporations to start ups, including eight of the top 10 global pharmaceutical companies by sales for 2014. SIL has longstanding, extensive relationships with multinational clients such as BMS, Baxter and Merck & Co. as well as emerging small to mid-sized companies such as Achillion Pharmaceuticals, Inc., Aquinox Pharmaceuticals, Inc. and Saniona AB.

Protection of its clients' intellectual property and data confidentiality - Since inception, the company has made it a strategic priority to safeguard clients' proprietary rights by using well established and strictly enforced intellectual property protection procedures. Sil has zero-tolerance policy for confidentiality breaches and data leakages.

Strong Financial Performance - The company has reported robust total revenue CAGR of 28 % and an impressive profit after tax (PAT) CAGR of 35% over FY2012-14. Exports accounted 95.1% of total revenues in FY15.

Outlook, Valuation and Recommendation -

At the upper band of the issue price, SIL is valued at 28x FY15 EPS of Rs. 8.79. With due consideration to factors like a) world-class infrastructure, systems and processes that comply with international standards to serve international markets, b) successful audits by regulatory authorities such as the FDA and EMA, c) diversified and attractive client base, d) proven track-record of successful delivery, reliability, cost efficiency & client satisfaction, e) strong past financial performance, e) historical trend of positive cashflow, f) favorable capital structure, we believe the Company's valuation is fairly priced as compared to its global peer Wuxi Pharmatech (SIL has a better return profile compared to Wuxi with FY15 margin of 33.5% (vs. Wuxi's 22.3%), ROE of 20.7% (vs 15.2%). we recommend "SUBSCRIBE" to the issue for a long term horizon.

Issue date	July 27- 29, 2015			
Issue size	Rs. 5.5 bn at upper end of the price band (Offer for sale)			
Face Value	Rs.10			
Price Band	Rs. 240 - 250 per share			
Lot size	60 equity Shares and in multiples of 60 equity shares thereof			
Issue structure	QIB: 45%, Biocon shareholders: 9% Retail: 32% Non – Institutional: 14%			
Industry	Pharmaceuticals (CRO)			
Equity shares post issue	200 mn equity shares			
Post issue market capitalization	Rs. 50 bn at upper price band			
Book Running Lead Managers	Axis Capital, Credit Suisse, Jefferies			
Registrar to the issue	Karyv Computershare Pvt. Ltd.			
Y/e 31 Mar (Rs. mn)	FY15	FY14	FY13	FY12
Total income	8,716	7,077	5,542	4,182
Growth (%)	23	27.6	32.5	29.5
EBITDA	2,928	2,226	1,727	1,386
EBITDA Margin (%)	33.5	31.4	31.1	33.1
Reported PAT	1,750	1,348	1,021	710
PAT margin (%)	20	19.04	18.40	16.97
Post issue EPS (Rs.)	8.79	6.77	5.13	3.56
Equity Capital	1,991	261	261	241
Networth	8,449	6,593	5,186	2,968
RoE (%)	20.7	20.4	19.7	23.9

Shareholding Pattern (%)	Pre Issue	Post Issue
Promoters group	85.5	74.5
Foreign & Cor. Bodies	11.1	11.1
Non promoters & non public	3.3	3.3
Public	-	11
Total	100	100



Objects of the issue

- 1) Achieve benefits of listing equity shares on the stock exchanges; and
- 2) The company intends to raise Rs528-550 crore which comprises offer for sale from the promoter group, Biocon. The net proceeds will not come to Syngene, it will be used by the promoter (Biocon) to expand its manufacturing capacity and to fund research and development expenditure.

Industry Overview

Contract Research Organisations (CROs) offer outsourced services to support discovery and development for R&D driven organisations across industrial sectors like pharmaceuticals, biotechnology, biopharmaceuticals, nutraceuticals, animal health, agro-chemicals, cosmetics and electronics. CRO services span in the range of R&D activities from NME discovery, development and manufacturing. Growth in the CRO market has historically been driven by growth in R&D spending and increased outsourcing of R&D activities.

Frost & Sullivan estimates that the global R&D expenditure for the pharmaceutical industry in 2014 was approximately US\$139 billion, of which US\$105 billion could have potentially been outsourced (Source: Frost & Sullivan Report). According to the Frost & Sullivan report, outsourcing penetration for the CRO market for development services as of 2014 is estimated to be 27.3% of the potential outsourcing market for development services, but is poised to grow to 38.7% in 2019, reflecting a compounded annual growth rate (CAGR) of 12.5%. The global CRO market for discovery services was estimated to be US\$14.7 billion in 2014 and is expected to reach US\$22.7 billion in 2018, reflecting a CAGR of 11.5% (2014-18), according to the IQ4I Report.

The global CRO market for development services was estimated to be \$28.8 billion in 2014 and is expected to reach US\$44.6 billion in 2018, reflecting a CAGR (2014-18) of 11.6%, according to the Frost & Sullivan report.

Key risks and concerns

Contracts are generally terminable on little or no notice period

Contracts are generally terminable without cause upon 30 to 90 days' notice by the client. Clients may terminate, cancel or delay contracts for various reasons, including client's decision to downsize its product development portfolios, the client's decision to change their outsourcing strategy and the client's dissatisfaction with company's performance, including the quality or accuracy of the data or reports provided and the ability to meet agreed upon schedules. In addition, certain contracts also allow for termination in the event of any change in the beneficial ownership of the promoter, Biocon or Syngene that results in a change of control.

Currency Risk

The company faces foreign exchange rate risk to the extent of income, expenses, assets or liabilities that are denominated in a currency other than the Indian Rupee. Almost all of its revenue from operations, a large portion of equipment purchases, a portion of its material costs and much of its debt and bank balances are denominated in US dollars. In addition, some of its export revenue is also denominated in other foreign currencies, principally the Euro.

Company is dependent on the continued outsourcing of R&D by various industrial sectors

The company is purely dependent upon the ability and willingness of its clients to spend on R&D at rates close to or at historical levels and to outsource the services. Its business could be adversely affected by any significant decrease in outsourced R&D expenditure by existing or potential clients.



STOCK BROKING, INVESTMENT BANKING, CORPORATE ADVISORY & INSURANCE

Disclaimer

Ajcon Global Services Ltd. is a fully integrated investment banking, merchant banking, corporate advisory, stock broking, commodity and currency broking. Ajcon Global Services Ltd. research analysts responsible for the preparation of the research report may interact with trading desk personnel, sales personnel and other parties for gathering, applying and interpreting information. Individuals employed as research analyst by Ajcon Global Services Ltd. or their associates are not allowed to deal or trade in securities that the research analyst recommends within thirty days before and five days after the publication of a research report.

We and our affiliates, officers, directors, employees and their relative may: (a) from time to time, have long or short positions in act as a principal in, and buy or sell the securities or derivatives thereof, of company (ies) mentioned herein or (b) be engaged in any other transaction involving such securities and earn brokerage.

The information and opinions in this report have been prepared by Ajcon Global Services Ltd. and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of Ajcon Global Services Ltd. While we would endeavour to update the information herein on a reasonable basis, Ajcon Global Services Ltd. is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent Ajcon Global Services Ltd. from doing so. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. Ajcon Global Services Ltd. will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. Ajcon Global Services Ltd. accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. Ajcon Global Services Ltd. or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

Ajcon Global Services Ltd. or its associates have not received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

Ajcon Global Services Ltd. encourages independence in research report preparation and strives to minimize conflict in preparation of research report. Ajcon Global Services Ltd. or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither Ajcon Global Services Ltd. nor Research Analysts have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Akash Jain, MBA (Financial Markets) research analyst of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months. Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

Ajcon Global Services Ltd. or its subsidiaries collectively or Research Analysts do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

It is confirmed that Mr. Akash Jain, MBA (Financial Markets) research analyst do not serve as an officer, director or employee of the companies mentioned in the report.

Ajcon Global Services Ltd. may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.

Neither the Research Analysts nor Ajcon Global Services Ltd. have been engaged in market making activity for the companies mentioned in the report.

Research Analyst

Akash Jain, MBA (Financial Markets)

Corporate Off. : 408, Express Zone, "A" Wing, Cello – Sonal Realty, Near Oberoi Mall,
Western Express Highway, Malad (East), Mumbai - 400 063. Tel : 91-22-67160400
mail : research@ajcon.net Website : www.ajcononline.com



Ajcon Global™
Your Friendly Advisor
Since 1986



STOCK BROKING, INVESTMENT BANKING, CORPORATE ADVISORY & INSURANCE

We submit that no material disciplinary action has been taken on Ajcon Global Services Ltd. by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject Ajcon Global Services Ltd. and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.



For research related queries contact:

Mr. Akash Jain – Vice President (Research) at research@ajcon.net, 022-67160431 (D)

CIN: L74140MH1986PLC041941

Website: www.ajcononline.com

Corporate and Broking Division

408 - (4th Floor), Express Zone, "A" Wing, Cello – Sonal Realty, Near Oberoi Mall and Patel's, Western Express Highway, Malad (East), Mumbai – 400063. Tel: 91-22-67160400, Fax: 022-28722062

Registered Office:

101, Samarth, Off. Hinduja Hospital, 151 Lt. P.N. Kotnis Road, Mahim (West), Mumbai – 400016. Tel: 022-24460335/36/40

Research Analyst

Akash Jain, MBA (Financial Markets)

Corporate Off. : 408, Express Zone, "A" Wing, Cello – Sonal Realty, Near Oberoi Mall, Western Express Highway, Malad (East), Mumbai - 400 063. Tel : 91-22-67160400
mail : research@ajcon.net Website : www.ajcononline.com